A 56-year-old man with Child-Pugh B cirrhosis (alcohol-related, now abstinent; SVR post-DAA for HCV) undergoes screening upper endoscopy. Esophageal findings from 25–40 cm show the structure marked **A**: large tortuous varices occupying 1/3 of the esophageal lumen, non-flattening with full insufflation, with multiple red wale marks and cherry-red spots. Platelets 78,000, INR 1.5, HVPG estimated 12 mm Hg. No prior variceal bleeding. Which of the following is the most appropriate PRIMARY PROPHYLAXIS strategy for this patient?

Question

A 56-year-old man with Child-Pugh B cirrhosis (alcohol-related, now abstinent; SVR post-DAA for HCV) undergoes screening upper endoscopy. Esophageal findings from 25–40 cm show the structure marked **A**: large tortuous varices occupying >1/3 of the esophageal lumen, non-flattening with full insufflation, with multiple red wale marks and cherry-red spots. Platelets 78,000, INR 1.5, HVPG estimated >12 mm Hg. No prior variceal bleeding. Which of the following is the most appropriate PRIMARY PROPHYLAXIS strategy for this patient?

Accepted Answer

C. Carvedilol (preferred agent adding alpha-1 blockade to reduce intrahepatic vascular resistance). ## Why Carvedilol is right

The structure marked **A** represents large esophageal varices with red-color signs (red wale marks and cherry-red spots) in a Child-Pugh B patient—a HIGH-RISK phenotype for variceal bleeding. According to Baveno VII Consensus (J Hepatol 2022) and current AASLD guidance, carvedilol is now the PREFERRED non-selective beta-blocker for primary prophylaxis in compensated cirrhosis because it combines non-selective beta-blockade with alpha-1 antagonism, reducing intrahepatic vascular resistance and improving hemodynamic response rates. For primary prophylaxis (no prior bleed), monotherapy with a non-selective beta-blocker (NSBB) OR endoscopic variceal ligation is appropriate; combination therapy is reserved for secondary prophylaxis (after a bleed). Carvedilol's superior hemodynamic profile and evidence for preventing first decompensation make it the preferred initial choice in this patient.

## Why each distractor is wrong

- **Propranolol titrated to 25% heart rate reduction or target 55–60 bpm**: While propranolol is a valid non-selective beta-blocker for primary prophylaxis, it lacks the alpha-1 blockade that carvedilol provides. Current Baveno VII and AASLD guidance favor carvedilol over propranolol or nadolol in compensated cirrhosis due to superior intrahepatic hemodynamic benefit and improved response rates.

- **Endoscopic variceal ligation (EVL) repeated every 2–4 weeks until obliteration**: EVL is an acceptable alternative to NSBB monotherapy for primary prophylaxis of high-risk varices, but it is NOT more appropriate than carvedilol as a first-line choice. EVL requires repeated procedures and is typically reserved for patients who cannot tolerate or fail pharmacologic therapy, or as an adjunct in secondary prophylaxis.

- **Combination of non-selective beta-blocker and EVL initiated immediately**: Combination therapy (NSBB + EVL) is the standard for SECONDARY prophylaxis (after a variceal bleed), not primary prophylaxis. This patient has no prior bleeding, so monotherapy (carvedilol) is appropriate and sufficient at this stage.

**High-Yield:** Carvedilol is now the preferred NSBB for primary prophylaxis in compensated cirrhosis (Baveno VII); combination NSBB + EVL is reserved for secondary prophylaxis after a bleed.

[cite: Baveno VII Consensus J Hepatol 2022; AASLD Practice Guidance Portal Hypertension 2024; Sleisenger and Fordtran 11e Ch 92]

Answer

A. Propranolol titrated to 25% heart rate reduction or target 55–60 bpm

Answer

B. Combination of non-selective beta-blocker and EVL initiated immediately

Answer

D. Endoscopic variceal ligation (EVL) repeated every 2–4 weeks until obliteration

Explanation

Why Carvedilol is right

Why each distractor is wrong

Practice similar questions

Join our NEET PG community